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Abstract
Although a number of studies have demonstrated the influence of ABO blood group on plasma
levels of von Willebrand factor (VWF), the nature of this association and its clinical importance is
still largely unknown.
In this review, the most recent advances in our understanding of the mechanisms by which ABO
blood group determines plasma VWF levels and their clinical impact will be discussed.
Review
Introduction
Von Willebrand factor (VWF) is a large adhesive glycopro-
tein synthesized by endothelial cells and megakaryocytes
that circulates in the plasma as a series of heterogeneous
multimers [1-3].
VWF has two major functions in hemostasis. First, it is
essential for platelet-subendothelium adhesion and plate-
let-to-platelet interactions as well as platelet aggregation
in vessels in which rapid blood flow results in elevated
shear stress. Second, VWF is the specific carrier of factor
VIII (FVIII) in plasma and protects it from proteolytic deg-
radation, prolonging its half-life in circulation and effi-
ciently localizing it at the site of vascular injury [4].
While a deficiency of VWF is responsible for a hemor-
rhagic diathesis (von Willebrand disease, VWD) [5], there
are increasing evidences that elevated VWF levels repre-
sent an important thrombotic risk factor [6,7].
Besides the VWF gene (12p12), it is well established that
other gene loci exert major quantitative effects on VWF
plasma levels. The most important of these loci has been
shown to be the ABO blood group locus on chromosome
9q34 [8,9].
The antigens of the ABO system (A, B, and H determi-
nants, respectively) consist of complex carbohydrate mol-
ecules. The A  and  B  alleles encode slightly different
glycosyltransferases that add N-acetylgalactosamine and
D-galactose, respectively, to a common precursor side
chain, the H determinant, converting it into A- or B-anti-
gens. The O alleles do not encode a functional enzyme
and consequently OO carriers, who lack such transferase
enzymes, continue to express the basic, unmodified, H-
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antigen with a fucose moiety attached to precursor oli-
gosaccharide chains[10].
The nature of the interaction between ABO blood group
antigens and plasma VWF levels along with its clinical
implication will be discussed in this review.
Studies on the influence of ABO blood groups on VWF 
levels
Several studies have documented the influence of ABO
blood groups on plasma VWF levels [11-13]. In a large
twin study, Orstavik and colleagues [14] found that 66
percent of the total variation in plasma VWF levels was
genetically determined and that 30 percent of this genetic
component was explained by ABO blood group. Other
studies have consistently reported that group O subjects
have lower plasma VWF levels than non-O individuals.
Indeed, in a large study of 1117 healthy individuals con-
ducted by Gill and colleagues [15], plasma VWF levels
were lowest in group O (mean von Willebrand factor anti-
gen [VWF:Ag] 75 IU/dL) and highest in group AB subjects
(mean VWF:Ag 123 IU/dL). From the same study also
emerged that the influence of ABO blood groups on
plasma VWF levels can make difficult the diagnosis of type
1 VWD since the normal range for VWF:Ag in group O
individuals extends below 50 IU/dL (mean ± 2SD: 36–
157 IU/dL), which is commonly accepted as the lower
normal limit. In fact the authors, investigating the distri-
bution of ABO blood groups in 114 patients with type 1
VWD, found a predominance of blood group O with a fre-
quency significantly different from the general population
(77% group O, 18% group A, 4% group B in type 1 VWD
patients versus 45% group O, 45% group A, 7% group B
in healthy individuals, P < 0.001) [15]. However, the pri-
mary importance of the bleeding history in the clinical
decision to diagnose and treat type 1 VWD was stressed by
Nitu-Whalley and colleagues in a retrospective study on
the re-classification of 246 previously diagnosed type 1
VWD patients [16].
In addition to the above mentioned VWF antigenic varia-
bility, Moeller and colleagues [17] described variations in
VWF activity (von Willebrand factor ristocetin cofactor,
VWF:RCo) in persons with different ABO groups with
individuals of group O that exhibited VWF:RCo levels sig-
nificantly lower than those in the non-O group.
Miller and colleagues [18] studied the effect of ABO blood
type and race on plasma VWF levels and found that Cau-
casians had significantly lower levels than African-Ameri-
cans. Interestingly, ABO and race showed independently
effects accounting for 19 and 7 percent of the total vari-
ance in VWF:Ag levels, respectively.
Besides the studies on ABO phenotype, other investigators
have examined the relationship between ABO genotype
and plasma VWF levels [19-21]. According with previous
studies, lowest plasma VWF levels were present in geno-
type OO individuals. However, all groups also found that
individuals heterozygous for the O allele (genotypes AO,
BO) had significantly lower plasma VWF levels then those
not carrying an O allele (genotypes AA, AB, BB).
Finally, other investigators studied the influence of Secre-
tor blood group, characterized by a fucose as terminal
sugar, on plasma VWF levels and found significantly
higher VWF levels in individuals homozygous for the Se
allele (genotype SeSe) compared to those heterozygous
(genotype Sese) [22].
The nature of the association
Von Willebrand factor is one of the few non-erythrocytic
proteins that express ABO antigens. ABH oligosaccaride
structures have been identified on the N-linked oligosac-
charide chains of VWF located in the A1 domain, which
contains the binding site for platelet glycoprotein Ib
(GPIb) I [23]. The importance of VWF glycosilation in
mediating the effect of ABO blood group on VWF levels is
well demonstrated by the observation that aberrant
endothelial expression of a glycosyltranferase (N-acetylga-
lactosaminyltranferase) results in altered VWF glycosila-
tion and heightened clearance in mice [24]. O'Donnell
and colleagues found a direct relationship between ABO
genotype, A transferase expression and the amount of A
antigen expressed on circulating VWF [25]. Similarly,
Morelli and colleagues [26] demonstrated an allele spe-
cific, dosage dependent effect of the ABO alleles on VWF
and FVIII levels and on the degree to which VWF was
loaded with A and B antigens. Furthermore, A and B anti-
gens expressed on VWF explained about 18 percent of the
variation in plasma VFW levels.
The mechanism by which ABH determinants on plasma
VWF influence plasma VWF levels is still unknown and
several hypotheses have been made during the last years
[9]. While the in vitro removal of A and B antigens from
purified plasma VWF decreases VWF activity but not its
antigenic level or binding to collagen [27], the detection
of lower levels of all three in type O individuals suggests
that ABO antigens in vivo influence the rate of synthesis or
proteolysis/clearance of the whole VWF molecule rather
than its function or multimeric structure [17].
The hypothesis that ABO blood group influences the rate
of biosynthesis/secretion of VWF in endothelial cells is
difficult to study, as glycan structures of VWF synthesized
in vitro differ significantly from those of plasma VWF [28].
Furthermore, in vivo data do not support this theory as
the total increase in VWF after infusion of desmopressinThrombosis Journal 2007, 5:14 http://www.thrombosisjournal.com/content/5/1/14
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was not significantly different between group O and non-
O individuals [29].
However, a more probable explanation for reduced VWF
levels in blood group O individuals involves a decreased
survival.
A central role for VWF glycan in determining the rate of
hepatic clearance has been demonstrated in both animal
models and humans. Changes in the glycosylation pattern
of VWF in a mouse strain with altered expression of an N-
acetylgalactosaminyltransferase gene resulted in low VWF
levels, possibly because of an accelerated clearance [24].
Another direct link between VWF glycosylation and clear-
ance comes from the study by Ellies and colleagues [30]
on mice with absence of the enzyme ST3Gal-IV, which
mediates the attachment of sialyl groups to terminal
galactose residues. In ST3Gal-IV-deficient mice, the half-
life of endogenous VWF was reduced two-fold. Similar
results were observed by Sodetz and colleagues in rabbits
[31]. A similar association between reduced ST3Gal-IV-
mediated sialylation and reduced plasma VWF levels was
also found in humans [31]. These data indicate that sia-
lylation is important to prevent premature clearance via
receptors that recognize non-sialylated terminal galactose
residues, like the hepatic asialoglycoprotein receptor.
Nossent and colleagues [32] used a mathematical
approach and estimated that half-life of endogenous VWF
is two hours longer than in the non-O population. Addi-
tional evidence that blood group O determinants on VWF
are associated with increased clearance is provided by
observations that infused FVIII (either plasma-derived or
recombinant) disappears more rapidly in blood group O
than in non-group O hemophilia A patients [33]. As
regards the mechanism by which ABH structures on VWF
may influence clearance rates, O'Donnell et al. originally
proposed that clearance of VWF is mediated via the H-
antigen by hepatic receptors specific for fucose exposing
glycoproteins [25]. However, the subsequent finding that
subjects with the Bombay phenotype, who totally lack H-
antigen on VWF and are non-secretors (no H substance in
plasma), have even lower VWF levels than blood group
OO carriers seems to be in conflict with this model [34].
Recent studies have suggested that ABO blood group
determinants may be important in influencing the suscep-
tibility of plasma VWF to proteolysis by ADAMTS13 (a
disintegrin and metalloproteinase with thrombospondin
type-1 repeats-13) metalloprotease [9]. Bowen [35] puri-
fied VWF from individuals of different ABO blood groups
and then incubated with human plasma-derived
ADAMTS13. Mulimeric analysis and collagen-binding
assays both demonstrated that proteolysis was signifi-
cantly faster for group O VWF compared to non-O VWF.
Thus, while carbohydrate structure has previously been
shown to protect VWF from proteolytic degradation in
plasma [36], the recent literature data show that a reduc-
tion in the number of sugars on the oligosaccharide
chains of VWF is associated with an increased susceptibil-
ity to cleavage by ADAMTS13 [9]. Indeed, Bombay pheno-
type was found to be associated with an increased
susceptibility to ADAMTS13 proteolysis [34]. The patho-
genic mechanism by which ABO blood group influences
the susceptibility to cleavage by ADAMTS13 is still
unknown but two N-linked potential glycosilation sites
(asparagines 1515 and 1574) are located in close proxim-
ity to the ADAMTS13 cleavage site (Tyr1605-Met1606
bond within the A2 domain). Thus, the oligosaccharide
chain composition may be involved in stabilizing the con-
formation of this VWF region, such that the removal of
terminal sugar allows the A2 domain to adopt a confor-
mation more permissive for ADAMTS13 cleavage.
Clinical implications
A number of studies have demonstrated a relationship
between ABO blood group and hemostasis. Indeed, a
higher rate of bleeding complications has been described
in patients belonging to group O [37,38] and blood group
O individuals are consistently overrepresented in patients
with inherited bleeding disorders [15]. By contrast, an
association between non-O blood groups and the risk of
arterial thromboembolic disease, including ischemic
heart disease and peripheral vascular disease, has been
recognised by several studies [39-42]. Results from the
Hoorn study [43] indicated that blood group non-O was
associated with a twofold increased cardiovascular mor-
tality compared with blood group O (RR 2.08 [95% CI
0.85–5.07]). The increased risk of venous thromboembo-
lism in non-O individuals has also been reported [44-47].
Interestingly, Morelli and colleagues [48] found that carri-
ers of non-O alleles had a twofold increased risk of a first
deep vein thrombosis and that the non-OO  genotypes
strongly influenced the risk of thrombosis in FV Leiden
carriers. On the other hand, both arterial and venous
thrombotic risks have been related to VWF levels [49-51].
However, only few studies have examined the effect of
VWF levels on the association between ABO blood type
and thrombosis.
To elucidate the role of the ABO blood group, VWF and
FVIII in the process of deep vein thrombosis, a popula-
tion-based patient-control study on 301 consecutive
patients and 301 controls was performed by Koster and
colleagues [49]. In univariate analysis the authors found
that the risk of thrombosis increased with increasing VWF
and FVIII levels and was higher in non-O subjects than in
those of group O. However, in multivariate analysis only
FVIII remained as a risk factor, suggesting a close relation-
ship between blood group and VWF concentration.Thrombosis Journal 2007, 5:14 http://www.thrombosisjournal.com/content/5/1/14
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Tirado and colleagues [52] analyzed 250 patients with
venous thrombosis and 250 unrelated controls and found
higher VWF levels in non-O group, which was more fre-
quent in patients. However, the risk attributed to VWF was
strongly dependent on blood groups as it disappeared
after adjusting for the ABO groups. Similar results were
found by Ohira and colleagues [53] in the Longitudinal
Investigation of Thromboembolism Etiology (LITE)
study.
On the whole, the results of these studies indicate that,
compared with type O, non-O individuals could have an
increased thrombotic risk via having higher VWF-FVIII
levels. However, not all studies agree with these findings
as some authors found that the association between VWF
and the risk of cardiovascular mortality was independent
of blood group [40,43].
Conclusion
A number of studies demonstrates that ABO blood group
influences plasma levels of VWF. Recent investigations
seem to indicate an altered susceptibility to cleavage by
ADAMTS13 as an important mechanism by which ABO
group can affect the rate of VWF catabolism. However, the
elucidation of the physiology of glycan structures of VWF
will help to understand the mechanisms by which blood
group contribute to the thrombotic risk.
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